Login / Signup

Apraglutide, a novel once-weekly glucagon-like peptide-2 analog, improves intestinal fluid and energy absorption in patients with short bowel syndrome: An open-label phase 1 and 2 metabolic balance trial.

Johanna EliassonMark K HvistendahlNanna FreundFederico BolognaniChristian MeyerPalle Bekker Jeppesen
Published in: JPEN. Journal of parenteral and enteral nutrition (2022)
Once-weekly 5 mg apraglutide was well tolerated in patients with SBS-II and SBS-IF and significantly improved the absorption of fluids, electrolytes, and energy.
Keyphrases
  • study protocol
  • clinical trial
  • phase iii
  • ionic liquid
  • phase ii
  • case report
  • randomized controlled trial
  • solid state
  • open label